Simulation of a plant for the production of L1 protein from Escherichia coli for the Human Papillomavirus (HPV) vaccine.
Simulación de una planta de producción de proteína L1 a partir de Escherichia coli para la vacuna contra el Virus del Papiloma Humano (HPV)
Article Sidebar
La Revista ofrece Acceso Abierto bajo una licencia Creative Commons Attibution License
Esta obra está bajo una Licencia Creative Commons Atribución-NoComercial 4.0 Internacional.
Main Article Content
HPV infection is one of the most prevalent sexually transmitted diseases, annually 80% of sexually active persons are infected by this virus at some time in their lives. In recent years, various bacteria such as Escherichia coli have been used to produce HPV L1 VLP vaccine instead of expensive eukaryotic systems. Considering that a key feature of L1 is its high immunogenicity, the aim of this work was to simulate a production plant of this protein from E. coli by proposing a bioprocess that allows cost reduction which could be used in other research for the analysis of HPV vaccine performance. The production plant was simulated using SuperPro Designer® v10.0 software. From the analyses of the simulation of the manufacturing process and the reports on the overall costs of the system, it is possible to determine that the annual costs are estimated at approximately 32 million USD, also, the cost result allows inferring that each dose would have a value of 0.19 USD/unit, being the most relevant component the manufacturing operating cost.
Downloads
Article Details
Begum Akuzum1,†, Sinae Kim2, 3,†, Tam Thanh Nguyen2, 3,†, J. H., Lee3, S., , Eunhye Kim2, 3, J. K., Choi1, Y., , Hyunjhung Jhun3, 4, Lee5, Y., Kim6, H., Sohn7, D. H., & , Soohyun Kim1, 2. (2018). L1 Recombinant Proteins of HPV Tested for Antibody Forming Using Sera of HPV Quadrivalent Vaccine. Immune Network, 18(3), 1–13.
Boxus, M., Fochesato, M., Mertens, E., Dendouga, N., Brendle, S., Balogh, K. K., Christensen, N. D., & Giannini, S. L. (2016). Broad Cross-Protection Is Induced in Preclinical Models by a Human. 90(14), 6314–6325. https://doi.org/10.1128/JVI.00449- 16.Editor
Chen, Y., Liu, Y., Zhang, G., Wang, A., Dong, Z., Qi, Y., Wang, J., Zhao, B., Li, N., & Jiang, M. (2016). Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic. Virus Research, 220, 97–103. https://doi.org/10.1016/j.virusres.2016.04.017
Duarte, L. S., Matte, C. R., Dall Cortivo, P. R., Nunes, J. E. S., Barsé, L. Q., Bizarro, C. V., & Ayub, M. A. Z. (2021). Expression of Bacillus amyloliquefaciens transglutaminase in recombinant E. coli under the control of a bicistronic plasmid system in DO-stat fed-batch bioreactor cultivations. Brazilian Journal of Microbiology, 52(3), 1225–1233. https://doi.org/10.1007/s42770-021-00521-3
Garbuglia, A. R., Lapa, D., Sias, C., Capobianchi, M. R., & Del Porto, P. (2020). The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease. Frontiers in Immunology, 11(February), 1–14. https://doi.org/10.3389/fimmu.2020.00188
Ghorban Hosseini, N., Tebianian, M., Farhadi, A., Hossein Khani, A., Rahimi, A., Mortazavi, M., Hosseini, S. Y., Taghizadeh, M., Rezaei, M., & Mahdavi, M. (2017). In Silico Analysis of L1/L2 Sequences of Human Papillomaviruses: Implication for Universal Vaccine Design. Viral Immunology, 30(3), 210–223. https://doi.org/10.1089/vim.2016.0142
Namvar, A., Bolhassani, A., Javadi, G., & Noormohammadi, Z. (2019). In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine. Scientific Reports, 9(1), 1–22. https://doi.org/10.1038/s41598-019-51679-8
Roos, N., Breiner, B., Preuss, L., Lilie, H., Hipp, K., Herrmann, H., Horn, T., Biener, R., Iftner, T., & Simon, C. (2020). Optimized production strategy of the major capsid protein
HPV 16L1 non-assembly variant in E. coli. Protein Expression and Purification, 175, 105690. https://doi.org/10.1016/j.pep.2020.105690
Wang, R., Pan, W., Jin, L., Huang, W., Li, Y., Wu, D., Gao, C., Ma, D., & Liao, S. (2020).
Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Letters, 471(September 2019), 88–102. https://doi.org/10.1016/j.canlet.2019.11.039
Yazdani, Z., Rafiei, A., Valadan, R., Ashrafi, H., Pasandi, M. S., & Kardan, M. (2020). Designing a potent L1 protein-based HPV peptide vaccine: A bioinformatics approach. Computational Biology and Chemistry, 85, 107209. https://doi.org/10.1016/j.compbiolchem.2020.107209
Yousefi, Z., Aria, H., Ghaedrahmati, F., Bakhtiari, T., Azizi, M., Bastan, R., Hosseini, R., & Eskandari, N. (2022). An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy. Frontiers in Immunology, 12(January), 1–11. https://doi.org/10.3389/fimmu.2021.805695
Zhang, B., Yin, S., Wang, Y., Su, Z., & Bi, J. (2021). Cost-effective purification process development for chimeric hepatitis B core (HBc) virus-like particles assisted by molecular dynamic simulation. Engineering in Life Sciences, 21(6), 438–452. https://doi.org/10.1002/elsc.202000
